Oncolytics Biotech
ONCY
46 hedge funds and large institutions have $1.21M invested in Oncolytics Biotech in 2024 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
10% more capital invested
Capital invested by funds: $1.1M → $1.21M (+$107K)
10% more funds holding
Funds holding: 42 → 46 (+4)
0.15% more ownership
Funds ownership: 1.55% → 1.71% (+0.15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$102K |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$44.7K |
| 3 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$27.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$26K |
| 5 |
Goldman Sachs
New York
|
+$17.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$69K |
| 2 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$34.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$12.3K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$11.3K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$6.71K |
ONCY Hedge Fund Activity: Q4 2024 in Review
46 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q4 2024, worth a combined $1.21M — up 9.7% from $1.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ONCY positions and 6 closed out — a net gain of 4 holders — while 14 added to existing stakes and 7 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $102K. The largest seller was Citadel Advisors, exiting entirely with an estimated $69K sold.
- 46 institutional investors held Oncolytics Biotech (ONCY) as of Q4 2024, up from 42 in Q3 2024.
- Funds reported $1.21M of Oncolytics Biotech stock for Q4 2024, up 9.7% quarter-over-quarter.
- 10 funds opened new Oncolytics Biotech positions in Q4 2024 and 6 closed out, a net change of +4 holders.
- The largest Oncolytics Biotech buyer in Q4 2024 was Virtu Financial, an estimated $102K added.
- The largest Oncolytics Biotech seller in Q4 2024 was Citadel Advisors, an estimated $69K sold.
Based on aggregated 13F filings for Q4 2024.